LivaNova PLC Gets a Hold Rating from Canaccord Genuity

By Austin Angelo

In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Hold rating on LivaNova PLC (NASDAQ: LIVN), with a price target of $76. The company’s shares closed yesterday at $82.04, close to its 52-week high of $82.12.

Mills wrote:

“We stay HOLD rated on LIVN coming out of constructive meetings with management on the road last week. We continue to believe the firm possesses intriguing long-term growth initiatives –in transcatheter mitral valve replacement (TMVR), heart failure (HF) and treatment-resistant depression (TRD) – but anticipate these segments will take several years to materialize and likely require additional M&A and material R&D spending before either the TMVR or HF initiatives could potentially contribute to LIVN’s top- and bottom-line growth profiles. That said, we sensed incrementally stronger conviction from management regarding both robust GM expansion potential as well as low-DD revenue growth from the emerging markets (ROW) business. Taken together, we management seems confident it can deliver merger integration cost synergies that the think these drivers could help the firm hit or exceed its guidance in 4Q:17.”

According to, Mills is a 5-star analyst with an average return of 17.5% and a 62.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.

Currently, the analyst consensus on LivaNova PLC is Moderate Buy and the average price target is $81.60, representing a -0.5% downside.

In a report issued on November 6, BTIG also maintained a Hold rating on the stock.

LivaNova PLC’s market cap is currently $3.91B and has a P/E ratio of 70.12. The company has a book value ratio of 2.0656.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LivaNova Plc is a global medical technology company specializing in the areas of Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management. It provides its services to patients, healthcare professionals and healthcare systems. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.